Engineering approaches aimed at reshaping immune responses featured prominently. A new study designed a CLDN18.2-targeting T-cell engager using RFdiffusion, showing that dendritic-cell supplementation via IL-12 and CXCL9/CXCL10 signaling was needed for durable antitumor effects. The result fits a broader pattern: effective cellular therapy is increasingly framed as an immune ecosystem problem, where target engagement must be paired with supportive stimulation to prevent early escape. Teams developing next-generation immuno-oncology candidates will likely prioritize combination biology and immune context markers as they refine payloads and stimulation strategies.